1
|
Kawamura M, Kobashi Y, Tanaka H, Bohno-Mikami A, Hamada M, Ito Y, Hirata T, Ohara H, Kojima N, Koretsune H, Gunji E, Fukunaga T, Inatani S, Hasegawa Y, Suzuki A, Takahashi T, Kakinuma H. Discovery of Novel Pyrazolylpyridine Derivatives for 20-Hydroxyeicosatetraenoic Acid Synthase Inhibitors with Selective CYP4A11/4F2 Inhibition. J Med Chem 2022; 65:14599-14613. [DOI: 10.1021/acs.jmedchem.2c01089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Madoka Kawamura
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Yohei Kobashi
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Hiroaki Tanaka
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Ayako Bohno-Mikami
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Makoto Hamada
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Yuji Ito
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Takashi Hirata
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Hiroki Ohara
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Naoki Kojima
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Hiroko Koretsune
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Emi Gunji
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Takuya Fukunaga
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Shoko Inatani
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Yoshitaka Hasegawa
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Akinori Suzuki
- Pharmaceutical Sciences Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Teisuke Takahashi
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| | - Hiroyuki Kakinuma
- Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama331-9530, Japan
| |
Collapse
|
2
|
Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 2005; 41:175-93. [PMID: 16258232 DOI: 10.1540/jsmr.41.175] [Citation(s) in RCA: 189] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Cytochrome P450s (P450) metabolize arachidonic acid (AA) to hydroxyeicosatetraenoic acids (HETEs) and epoxyeicosatrienoic acids (EETs). Among these eicosanoids, 20-HETE is formed in a tissue and cell-specific fashion and plays an important role in the regulation of vascular tone in the brain, kidney, heart and splanchnic beds. 20-HETE is a potent vasoconstrictor produced in vascular smooth muscle (VSM) cells. It depolarizes VSM by blocking the open-state probability of Ca2+-activated K+-channels. Inhibitors of the formation of 20-HETE block the myogenic response of renal and cerebral arterioles in vitro and autoregulation of renal and cerebral blood flow in vivo. The formation of 20-HETE in vascular smooth muscle is stimulated by angiotensin II, endothelin and norepinephrine and is inhibited by nitric oxide (NO). 20-HETE also stimulates mitogenic and angiogenic responses in vitro and in vivo. Changes in the production of 20-HETE have been observed in ischemic cerebrovascular diseases, cardiac ischemia-reperfusion injury, kidney diseases, hypertension, diabetes, uremia, toxemia of pregnancy. The physiological and pathophysiological role of 20-HETE in the regulation of vascular tone are being revealed by the use of newly developed inhibitors of the synthesis of 20-HETE and 20-HETE analogs. The present review summarizes recent findings implicating a critical role for 20-HETE in altering cardiovascular function in a variety of pathological conditions.
Collapse
Affiliation(s)
- Noriyuki Miyata
- Medicinal Research Laboratory, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
| | | |
Collapse
|